logo
Ottawa Airport Authority opposed to proposed housing development on Riverside Drive

Ottawa Airport Authority opposed to proposed housing development on Riverside Drive

CTV News18-06-2025

An Air Canada plane takes off from the airport, Monday, July 8, 2024 in Ottawa. THE CANADIAN PRESS/Adrian Wyld
The City of Ottawa's Planning and Housing Committee has approved a zoning amendment for a proposed housing development on Riverside Drive that is facing opposition from the Ottawa International Airport Authority.
The Taggart Group is proposing a development that would add 660 units in a mix of single-detached and semi-detached homes, townhouses, and apartments in four mid- to high-rise buildings. City staff recommend councillors approve the zoning change to allow low-rise development including single and semi-detached dwellings and new height limits.
Staff say in a report prepared for committee that the zoning amendments align with applicable policies for the area and the land sits outside the zones closest to the airport.
Councillors on the committee voted 8 to 3 in favour of the zoning change. Riley Brockington, Laine Johnson, Theresa Kavanagh, Clarke Kelly, Catherine Kitts, Tim Tierney, Ariel Troster, and Jeff Leiper voted in favour. Laura Dudas, Cathy Curry and Wilson Lo voted against.
Planning committee
Ottawa's Planning and Housing Committee meets June 18, 2025. (Kimberley Fowler/CTV News Ottawa)
Airport Authority opposes development
Joel Tkach, vice‑president of business development & marketing at the Ottawa International Airport Authority, spoke to committee to express the airport's opposition to the development.
'This site sits underneath the flight path of Runway 14 32 – YOW's longest – and within the circuit loop for general aviation and flight training on Runway 04 22 – our shortest,' he said. 'On average, eighty aircraft movements occur here daily, at altitudes between 50 to 150 metres. Although the proposed residential development land lies just barely outside the Airport Operating Influence Zone, noise doesn't respect lines on a map.'
Airport zoning map
A map showing Ottawa International Airport zoning regulations. The magenta star represents the site of a proposed housing development at 3930 Riverside Dr. (City of Ottawa)
City staff say a noise feasibility assessment was done one the site to review both roadway traffic and aircraft noise.
'Typical commercial windows are expected to be sufficient to attenuate aircraft noise; in addition, a detailed noise assessment will be required at the time of site plan control review and approval for specific noise control measures,' the report said.
Tkach said, however, the development could harm airport operations.
'We've seen what happens when homes encroach on airports. Montreal‑Trudeau, Toronto‑Pearson, and Toronto-Billy Bishop downtown have all endured waves of complaints, political pressure, curfews, and therefore lost air service,' he said.
Tkach said the airport received 140 noise complaints from approximately 85 homes last year.
'We confirm that residents will endure constant overhead traffic from heavy jets and low‑flying single‑engine aircraft. And guess what? A note on title about airport proximity does nothing to comfort someone who can't sleep, can't concentrate, or can't enjoy their own home.'
Development designed to reduce noise
Kyle Kazda, development manager with Taggart, told committee the design of the project would help shield residents from noise.
'Part of the layout of the site from the beginning did consider the potential for impacts from both airport noise and traffic from Hunt Club and Riverside. This has informed the massing of the towers along those two major streets, which, at minimum would shield, from a traffic noise perspective, the low-rise residential from that exposure,' he said.
He said the low-rise buildings would use wall components, roof sheathing and insulation intended to dampen noise for residents inside.
'We also will be undertaking site-specific noise studies for the four apartment blocks on the site, which will include on-site receptors measuring aircraft noise and then ensuring that those building components also will properly attenuate noise to ensure residents are comfortable.'
Homebuyers and tenants would be informed in advance of the potential for noise when moving in, Kazda added.
Audrey Belanger, president of the Hunt Club Community Association, urged committee to approve the zoning amendment.
'The biggest mistake we and council members could make, is to think that our personal preferences are representative of everyone's needs,' she said in a statement to CTV News Ottawa.
'We need housing and infrastructure that meets all residents', current and future, needs and not just what we personally currently want or use.'
The report will go to full city council June 25.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Victory Square Technologies Reports 2024 Results: Revenue Growth, Strategic Investments, and Portfolio Progress
Victory Square Technologies Reports 2024 Results: Revenue Growth, Strategic Investments, and Portfolio Progress

Globe and Mail

time19 minutes ago

  • Globe and Mail

Victory Square Technologies Reports 2024 Results: Revenue Growth, Strategic Investments, and Portfolio Progress

Victory Square Reports $23 Million in Adjusted Revenue for 2024, Highlighting Portfolio Growth Vancouver, British Columbia--(Newsfile Corp. - June 30, 2025) - Victory Square Technologies Inc. (CSE: VST) (OTC Pink: VSQTF) ("Victory Square" or the "Company"), a venture builder that invests in and develops high-growth technology companies, is pleased to share a summary of key milestones and audited financial highlights for the year ended December 31, 2024. The Company delivered a year of meaningful progress across its portfolio, highlighted by record financial performance, strategic asset monetization, and accelerating growth in its healthcare investments. These results position Victory Square for continued execution, strong momentum and a clear vision for long-term shareholder value creation in 2025 and beyond. 2024 Financial and Strategic Highlights Adjusted Revenue: Victory Square generated approximately $23.0 million in adjusted revenue in 2024, up from $17.6 million in 2023. GAAP Revenue: $16.7 million in 2024, compared to $12.1 million in the prior year, representing a 39% year-over-year increase. Cost of Goods Sold (COGS): $10.4 million in 2024, compared to $6.6 million in 2023. Gross Margin: $6.4 million in 2024, compared to $5.5 million in 2023. Asset Monetization: Completed the sale of BlockX to Edge Total Intelligence Inc. (TSXV: CTRL) in Q3 2024 for $1.7 million in listed shares. Strong Balance Sheet: including $6.16 million in cash and marketable securities, providing ample resources to fuel future growth and pursue strategic initiatives. Please see SEDAR+ for the Company's condensed consolidated audited financial statements and MD&A for audited annual consolidated financial statements for the year ended December 31, 2024. Hydreight Technologies: A Scalable Health Platform Hydreight Technologies Inc. (TSXV: NURS), a digital health company incubated by Victory Square, continued to scale its mobile wellness and telehealth platform across the U.S., achieving: $16.0 million in GAAP revenue for FY2024, up 39% YoY, and $22.3 million in adjusted revenue, up 31% YoY. Q1 2025 revenue of $6.53 million, up 34% YoY, with positive net income and adjusted EBITDA of $163,000. National recognition including rankings on the Deloitte Technology Fast 50 (Canada, #9), Fast 500 (North America, #56), and Ranked #13 on the Americas' Fastest Growing Companies 2025 list. Expanded National Network: Hydreight's platform now supports a network of over 3,000 registered nurses and 200+ prescribing physicians, serving patients across all 50 U.S. states. In addition to its core clinical provider base, Hydreight powers 400+ direct-to-consumer (D2C) healthcare brands and multiple white-label wellness partners, enabled by its scalable, plug-and-play infrastructure. On December 31, 2024, Victory Square held a 64% stake in Hydreight and continues to support its platform expansion and growth across new healthcare verticals. Health Innovation: Strategic Initiatives in 2024-25 Victory Square deepened its commitment to digital health through several key initiatives: VSDHOne Platform: A national, plug-and-play infrastructure for launching compliant direct-to-consumer healthcare brands across all 50 U.S. states. $10M Health Accelerator: Designed to incubate and invest in digital health startups focused on areas like biomarker testing, peptides, tele-pharmacy, and longevity. Pet Health: Victory Square is evaluating the growing pet wellness sector, building on prior virtual care solutions for animals. Insu Therapeutics: Advancing Oral Insulin for Diabetes Care Another promising digital health holding in Victory Square's portfolio is Insu Therapeutics Inc., a biotechnology company developing a non-invasive, oral insulin tablet for people living with diabetes. Victory Square holds approximately 22.8% ownership in Insu, which originated from research at the University of British Columbia (UBC). Insu's tablet uses a buccal delivery system —absorbing insulin through the inner cheek-bypassing the digestive tract and mimicking the body's natural insulin absorption via the liver. Preclinical trials have demonstrated insulin uptake comparable to injections, with prolonged glucose control and improved liver targeting. This innovation addresses a global health need. According to the International Diabetes Federation, over 500 million people worldwide are living with diabetes as of 2021, with the number expected to rise to 783 million by 2045. The global diabetes therapeutics market is projected to reach USD $118 billion by 2032 (Source: Market Research Future, Key highlights from Insu's development roadmap: Filed U.S. and international patents covering its novel tablet formulation and delivery polymers. Pursuing an FDA 505(b)(2) regulatory pathway, aiming to reduce development costs and timelines. Planning first-in-human trials in 2026, following preclinical success. Exploring domestic insulin tablet manufacturing to increase supply chain resilience. Insu is led by a multidisciplinary team: Dr. Anubhav Pratap-Singh (CEO & Co-Inventor): UBC Professor with 100+ publications and 7+ patents. Ammad Shorbaji (COO): Former senior executive at Sanofi with 25 years of regulatory and commercial experience. Dr. Tom Elliott (Medical Director): A leading Canadian endocrinologist with extensive clinical and academic credentials. Insu's work has garnered national and international media attention, with coverage from CBC, Global News, and other major outlets. This growing visibility supports early awareness as the company moves toward commercialization. Victory Square believes Insu Therapeutics represents both a strong commercial opportunity and a mission-aligned investment aimed at improving global health outcomes. The Company continues to support Insu through its next phase of growth and development. Outlook for 2025 and Beyond Victory Square enters 2025 with a strengthened balance sheet, a growing healthcare ecosystem, and a pipeline of high-potential assets. The Company's focus for 2025 includes: Scaling adoption of VSDHOne and expanding digital health verticals. Supporting growth of Hydreight and advancing Insu's clinical roadmap. Monetizing additional assets where appropriate. Continuing investment in biotech, health, and scalable technology platforms. " 2024 was a pivotal year for Victory Square," said Shafin Diamond Tejani, CEO. "We strengthened our balance sheet, scaled promising platforms, and unlocked value across the portfolio. We're committed to supporting innovation and creating long-term value for our shareholders in 2025 and beyond." Victory Square thanks its shareholders for their continued support and looks forward to sharing additional updates throughout the year. Sign up to VST's official newsletter at On behalf of the Board of Directors "Shafin Diamond Tejani" Director and Chief Executive Officer Victory Square Technologies Inc. For further information about Victory Square, please contact: Investor Relations Contact — Abbey Vogt Email: ir@ Telephone: 604 283-9166 Peter Smyrniotis — Director Telephone: 604 283-9166 ABOUT VICTORY SQUARE TECHNOLOGIES INC. Victory Square is a Venture Builder that provides investors a liquid way to invest in early-stage technology companies without buying a venture fund that requires accredited investor status or multi-year commitments. A diverse portfolio of 25+ innovative companies from around the world (founders come from: Ireland, Sri Lanka, Bulgaria, Australia, India, Brazil, the Middle East and North America) Sectors include: Digital Health, Artificial Intelligence (AI), Machine Learning (ML), Blockchain/Web3, Virtual & Augmented Reality (VR/AR), Gaming, Climate Tech Owner-operated (approx. 15% Management Ownership) Business Model: The Victory Square business model is to buy, build and invest in early stage tech companies. We spend upwards of 48 months with those companies until they're ready to spin-off or stand on their own. There are a couple of unique elements to our business model… We have unparalleled access to startups through our internal incubator and International network with over 250+ founders, investors, tech accelerators and venture capital firms from more than 60 countries. Second, our management team and advisors are actively involved in our investments from incubation through monetization, providing them with financial, operational, and strategic support to scale globally. We drive value by monetizing investments and reinvesting the gains in new innovations. The strategy was to build a self-sustaining business. VST is a publicly-traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTC Pink (VSQTF). For more information, please visit Forward-Looking Information This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is generally identifiable by use of the words "believes," "may," "plans," "will," "anticipates," "intends," "could," "estimates," "expects," "forecasts," "projects" and similar expressions, and the negative of such expressions. All statements other than statements of historical facts contained in this news release are forward looking statements. Forward-looking information in this news release includes, without limitation, statements regarding the future plans and objectives of the Company, execution of business strategy, future performance and future growth, business prospects, synergies and opportunities of the Company and its related subsidiaries, and other factors beyond the Company's control. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the Company's actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances at the date such statements are made, including, but not limited to the Company being able to capitalize on the acquired assets, the ability of acquired assets to maintain its value as presently contemplated, the synergies of the acquired assets with the Company's operations, and such other assumptions presented in the Company's disclosure record. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. All forward-looking information herein is qualified in its entirety by this cautionary statement, and GameOn disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Use of Non-GAAP Financial Measures This release contains references to non-GAAP financial measures Adjusted Revenue and Adjusted EBITDA. The Company defines Adjusted Revenue as gross cash income before adjustments for the deferred portion of business partner setup, license, and sponsorship fees and gross and accrued receipts from blockchain grant funding. The Company defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization and before (i) transaction, restructuring, and integration costs and share-based payments expense, and (iii) gains/losses that are not reflective of ongoing operating performance including inventory impairment. The Company believes that the measure provides useful information to its shareholders and investors in understanding the Company's 2023 operating cash flow and may assist in the evaluation of the Company's business relative to that of its peers more accurately than GAAP financial measures alone. This data is furnished to provide additional information and does not have any standardized meaning prescribed by GAAP. Accordingly, it should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP and is not necessarily indicative of other metrics presented in accordance with GAAP.

Mogo Announces Results of its Annual General Meeting of Shareholders
Mogo Announces Results of its Annual General Meeting of Shareholders

Globe and Mail

timean hour ago

  • Globe and Mail

Mogo Announces Results of its Annual General Meeting of Shareholders

The annual general meeting of shareholders (the "Meeting") of Mogo Inc. (NASDAQ: MOGO) (TSX: MOGO;) ("Mogo" or the "Company"), a digital wealth and payments business, was held today via live audiocast online and the Company is pleased to announce that all resolutions put forward, being the election of directors, the appointment of the auditors of the Company, and the renewal of the Company's stock option plan and all unallocated options thereunder, were approved. Each of the matters voted upon at the Meeting is discussed in detail in the Company's management information circular dated June 4, 2025 (the 'Circular'), which can be found under the Company's profile on SEDAR+ ( The total number of votes cast by shareholders by proxy or online at the Meeting was 9,529,647 votes, representing 38.94% of the Company's outstanding shares as at May 23, 2025. The voting results are detailed below. Election of Directors The nominees listed in the Circular were elected as directors of Mogo. Detailed results of the vote are as follows: Name of Nominee Votes For % Votes For Votes Withheld % Votes Withheld David Feller 6,744,975 97.55 169,436 2.45 Gregory Feller 6,744,490 97.54 169,921 2.46 Alex Shan 5,947,760 86.02 966,651 13.98 Christopher Payne 4,720,033 68.26 2,194,378 31.74 Kees van Winters 4,709,670 68.11 2,204,742 31.89 Kristin McAlister 4,710,470 68.13 2,203,942 31.87 Appointment of Auditor MNP LLP was re-appointed as auditor of the Company until the next annual general meeting of shareholders of the Company at remuneration to be fixed by the Company's board of directors. Detailed results of the vote are as follows: Votes For % Votes For Votes Withheld % Votes Withheld 9,496,273 99.65 33,373 0.35 Approval of Unallocated Options The Company's Stock Option Plan and all unallocated options under the Company's Stock Option Plan were renewed. Detailed results of the vote are as follows: Votes For % Votes For Votes Against % Votes Against 5,384,086 77.87 1,530,325 22.13 The Company has filed a report of voting results on all resolutions voted upon at the Meeting under its profile on SEDAR+ at About Mogo Mogo Inc. (NASDAQ:MOGO; TSX:MOGO) is a financial technology company with three distinct business lines: wealth, lending, and payments. Our mission is to provide consumers with innovative financial solutions that drive long-term financial health and success. We operate with a differentiated approach in each business, leveraging technology, behavioral science, and financial tools to create unique value propositions in our respective markets. Our wealth and lending businesses are focused on the Canadian market, where we are the only subprime consumer lender that also offers a holistic wealth and investing solution. This unique integration is designed to help consumers transition from borrowing and debt to long-term wealth building. Separately, our payments business is operated through Carta Worldwide, a wholly owned subsidiary that provides modern card issuing and processing solutions, primarily in Europe.

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

National Post

time2 hours ago

  • National Post

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Article content Article content – Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550 patients 1 – Article content Article content – Strengthened commercial preparations and manufacturing capabilities through partnerships with Osmind and Thermo Fisher Scientific, respectively – Article content – APPROACH expects to enroll 220 participants at approximately 45 clinical sites across Article content the United States 1 – Article content – Initiation of second CYB003 pivotal study EMBRACE and completion of CYB004 Phase 2 study in general anxiety disorder expected around mid-2025 1 – Article content – Cash totaled C$135 million as of March 31, 2025 – Article content This news release constitutes a 'designated news release' for the purposes of Cybin's prospectus supplement dated February 10, 2025, to its short form base shelf prospectus dated August 17, 2023, as amended December 22, 2023, April 8, 2024, and January 6, 2025. Article content TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported audited financial results for its fiscal year ended March 31, 2025, and recent business highlights. Article content 'During the past 12 months, we have continued to focus on building out the strong foundation that underpins the clinical and regulatory milestones we anticipate in the coming year,' said Doug Drysdale, Chief Executive Officer of Cybin. 'Heartened by U.S. Food and Drug Administration Commissioner Dr. Martin Makary's recent comments in support of prioritizing this innovative scientific work, as well as the burgeoning government and media attention the field is receiving, we remain steadfastly committed to advancing our two lead programs, CYB003 and CYB004, toward potential approval and commercialization.' Article content 'Developing novel therapies to address the unmet need in mental health care requires dedication, scientific rigor, and the integration of expertise across domains. To help us accelerate our clinical goals, we have entered into several strategic collaborations, including with Osmind and Thermo Fisher Scientific, and have formed strategic partnership agreements among our clinical trial sites. In this way, we leverage the competencies, resources, and infrastructures of these key stakeholders with a goal of expediting the development pathway. Cybin's lead clinical programs – CYB003, our Phase 3 pivotal program for the adjunctive treatment of major depressive disorder, and CYB004, our Phase 2 program in generalized anxiety disorder – continue to advance, and we look forward to sharing future updates.' Article content Recent Business and Pipeline Highlights: Article content The SPAs are designed to facilitate collaboration among sites, cultivate long-term partnerships, enhance efficiency in trial operations, and improve overall site performance. Article content Engaged Thermo Fisher Scientific, a world-class manufacturing partner, to provide U.S.-based manufacturing for the CYB003 program. Article content Thermo Fisher Scientific offers leading Contract Development and Manufacturing Organization services and has a successful track record across the manufacturing spectrum. Cybin broadened its existing strong relationship with Thermo Fisher Scientific to include the development of both the drug substance and drug product capsules for CYB003. Cybin has engaged Thermo Fisher Scientific as its manufacturing partner in the United States, including partnering with Thermo Fisher Scientific's pharma services sites in Florence, South Carolina, for Phase 3 clinical supply and future commercialization, and Cincinnati, Ohio, for Phase 3 capsule production. Article content Partnered with Osmind, a leading service provider to psychiatry practices in the U.S., with the objective of accelerating commercial preparation for clinical-stage pipeline. Article content Osmind advances psychiatry through technology and services to bring innovative mental health treatments to patients in need. Cybin expects to leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline. Article content Strengthened intellectual property portfolio with two additional U.S. patents in support of lead clinical programs CYB003 and CYB004. Article content To-date, Cybin's growing intellectual property portfolio comprises more than 90 granted patents and over 230 pending applications. The recently issued patents are as follows: Article content U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041. U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular injection, including CYB004. Article content Clinical Program Update Article content CYB003: Summary of Phase 2 12-Month Efficacy Data in MDD Patients Article content 100% of participants receiving two doses of 16 mg were responders. 71% of participants receiving two doses of 16 mg were in remission. Mean change from baseline in MADRS was approximately -23 points after two 16 mg doses. Article content CYB004: Phase 2 proof-of-concept study in generalized anxiety disorder ('GAD') is underway Article content The Phase 2 study is a randomized, double-blind study evaluating the safety and efficacy of CYB004 in participants with GAD, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed. The Phase 2 study is being conducted at sites in the U.S. and is expected to complete around mid-2025. 1 Article content Q4 and Fiscal-Year 2025 Financial Highlights Article content Cash totaled C$135 million as of March 31, 2025. Net loss was C$31 million for the quarter ended March 31, 2025, compared to a net loss of C$21 million in the same period last year. Net loss was C$113 million for the year ended March 31, 2025, compared to a net loss of C$78 million in the same period last year. Cash-based operating expenses consisting of research, general, and administrative costs totaled C$31 million for the quarter ended March 31, 2025, compared to C$24 million, in the same period last year. Cash-based operating expenses consisting of research, general, and administrative costs totaled C$100 million for the year ended March 31, 2025, compared to C$65 million, in the same period last year. Cash flows used in operating activities were C$21 million for the quarter ended March 31, 2025, compared to C$21 million in the same period last year. Cash flows used in operating activities were C$101 million for the year ended March 31, 2025, compared to C$69 million in the same period last year. Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Article content Notes: Article content There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'. Article content Cautionary Notes and Forward-Looking Statements Article content Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to complete its Phase 2 study for CYB004 around mid-year 2025; the ability of the Company to enroll participants and add additional clinical sites for the PARADIGM program; the Company's expectation to enroll 220 participants at approximately 45 clinical sites across the United States for the APPROACH study; initiation of EMBRACE study around mid-year 2025; the anticipated approval and commercialization of CYB003 and CYB004; the ability to accelerate commercial preparation of clinical-stage programs through the Company's partnership with Osmind; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the year ended March 31, 2025 and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Contacts Article content Investor & Media Contact: Article content Article content Gabriel Fahel Article content Article content Chief Legal Officer Article content Article content Cybin Inc. Article content Article content Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store